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Abstract
 .Fenofibrate, the hypolipidemic drug and peroxisome proliferator, was given to mice 0.23% wrw in the diet during 1–3
weeks and H O and TBARS steady state concentrations, liver chemiluminescence and antioxidant levels were measured.2 2
Administration of fenofibrate during 2 weeks induced an increase of 89% in H O steady state concentration. Spontaneous2 2
chemiluminescence was decreased by 57% during fenofibrate treatment, while no significant effect was observed on
TBARS concentration. Hydroperoxide-initiated chemiluminescence was decreased by 56% after 15 days of fenofibrate
treatment, probably due to an increase in endogenous antioxidant levels. Total and oxidized glutathione increased gradually
after fenofibrate administration, obtaining maximal increases of 67% and 58% respectively, after 22 days of treatment. An
increase of 55% was found in ubiquinol levels in treated mice, as compared with the controls. a-tocopherol content was
decreased by 51% in the liver of fenofibrate-treated mice. According to our findings, the high rate of H O production2 2
associated with peroxisome proliferation, would not lead to an increase in lipid peroxidation. This can be explained by the
presence of high levels of ubiquinols, which act as an antioxidant. The increased production of H O , would lead to DNA2 2
damage directly, and not through lipid peroxidation processes.
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1. Introduction
Hypolipidemic agents are known to produce hep-
atic peroxisome proliferation and induction of peroxi-
somal H O -producing oxidases in rats and mice2 2
w x1,2 . Increased levels of hydrogen peroxide can lead
to DNA damage and eventually to the development
w xof carcinogenesis, as suggested by Reddy et al. 3,4 .
) Corresponding author. Fax: q54 1 9627928.
Among the synthetic peroxisome proliferators, the
largest group consists of the amphipathic carboxyl-
ates, such as Wy-14,643, benzafibrate, ciprofibrate,
nafenopin, fenofibrate, and clofibric acid. Fenofi-
brate, an ester, is thought to be hydrolyzed to the
amphipathic carboxylic acid in cells. These com-
pounds are strong to moderate peroxisome prolifera-
w xtors and hepatocarcinogens in rodents 3 .
We have previously characterized a model of per-
oxisome proliferation induced by fenofibrate in which
we observed hepatomegaly, increased activities of
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acyl-CoA oxidase, catalase and urate oxidase, and
increased H O steady state concentrations in the2 2
w xliver of treated mice 5 .
It has been postulated that peroxisome prolifera-
tors-induced carcinogenicity would be related to bio-
logically active products of the proliferated peroxi-
somes rather than to a direct action of the compounds
w xthemselves or their metabolites 6 . The hepatocar-
cinogenic process due to long term administration of
 .peroxisome proliferators PPs would be a conse-
quence of the metabolic imbalance resulting from
increased peroxisomal enzyme activities and oxida-
w xtive stress 7 . H O induces increases in intracellular2 2
free Ca2q, activates Ca2qrcalmodulin-dependent pro-
tein kinase, and a kinase that phosphorylates the
ribosomal protein S6. S6 phosphorylation would be
involved in the stimulation of protein synthesis and
w xthe acquisition of cell growth competence 8 . In
addition, oxidants might stimulate the phosphotrans-
 .ferase activity of protein kinase C PKC and in-
crease the expression of the growth-competence-re-
lated proto-oncogenes c-fos, c-jun and c-myc. Activa-
tion of some of these proto-oncogenes has been
w xobserved in the liver of rodents treated with PPs 9 .
Since PPs do not directly activate the nuclear-
located peroxisome proliferator activated receptor
 .PPAR , an alternate hypothesis suggests that
metabolites of these drugs act directly via signal-
transduction pathways. Acyl-CoA derivatives of some
PPs have been found to greatly increase the activity
w xof PKC 10 . Phosphorylationrdephosphorylation of
key proteins is essential to the control of cell growth,
differentiation and proliferation. Orellana et al. have
shown that PPs-activated PKC could influence the
regulation of the epidermal-growth-factor system
which is involved in processes of cellular differentia-
w xtion and proliferation, and tumorigenesis 11 .
Peroxisome proliferators may cause oxidation of
w xmembrane fatty acids and lipid peroxidation 12,13 .
Goel et al. observed accumulation of lipofuscin – an
end product of free-radical-induced oxidative poly-
merization reactions – in liver during hepatocarcino-
w xgenesis by peroxisome proliferators 14 .
On the other hand, it has also been described that
some peroxisome proliferators such as clofibrate, and
phthalates produce an increase in the levels of
w xubiquinols in several tissues, including rat liver 15 .
Ubiquinols are the only liposoluble endogenous anti-
oxidants in animal tissues; they inhibit lipid peroxida-
w xtion and thus protect against oxidative damage 16 .
In this study, we continued the evaluation of the
w x  .previously presented model 5 , through: a lipid
peroxidation measurements, such as in vivo sponta-
neous chemiluminescence and thiobarbituric acid re-
 .active substances, b hydroperoxide-initiated chemi-
 .  .luminescence, c antioxidant levels, and d histo-
logic studies.
2. Materials and methods
2.1. Animals and treatment
 .Female Swiss mice 25–30 g were obtained from
School of Pharmacy and Biochemistry, University of
Buenos Aires, Argentina. Fenofibrate dissolved in
ethanol was incorporated into the feed, and the sol-
vent was evaporated to provide a final concentration
of 0.23% wrw. Animals were fed the treated diet for
1, 2 or 3 weeks. Control mice were fed normal diet
subjected to the same procedure but without the drug.
2.2. Preparation of mouse li˝er homogenates
Animals were sacrificed by cervical dislocation.
Mouse liver was excised and immediately placed in
saline solution at 0–28C and homogenized in a
medium consisting of 120 mM KCl and 30 mM
 .potassium buffer pH 7.4 at a ratio of 1 g of organ to
9 ml of solution, and centrifuged at 600=g for 10
min at 0–28C, to discard nuclei and cellular debris.
The supernatant, a suspension of preserved or-
ganelles, was termed ‘homogenate’.
2.3. Hydrogen peroxide steady state concentration
Steady state concentration of H O was measured2 2
in the incubation medium of liver slices after reach-
ing diffusion equilibrium. Tissue slices 0.1 mm thick
were incubated 10 min in 120 mM NaCl, 30 mM
 .phosphate buffer pH 7.4 at 308C and at a
tissuermedium ratio of 1r20. Samples of the incuba-
tion medium were diluted 1r2.5 with 100 mM phos-
 .phate buffer pH 7.4 containing 2.8 Urml
horseradish peroxidase and 40 mM p-hydroxyphenyl-
acetic acid as hydrogen donor and fluorescence inten-
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sity was measured at 317–414 nm. H O concentra-2 2
tion was determined by a standard calibration curve
and calculated by subtracting the value of a sample
treated with 0.1 mM catalase from the value of an
w xuntreated sample 5 .
2.4. In situ li˝er chemiluminescence
Control and treated mice were anesthetized with
 .urethane i.p. 1.5 grkg of weight . The liver surface
was exposed by laparotomy and chemiluminescence
was measured with a Johnson Foundation photon-
counter Johnson Research Foundation, University of
. w xPennsylvania, Philadelphia, PA 17 . Chemilumines-
cence was expressed in counts per second per unit of
 2.liver surface cpsrcm .
( )2.5. Thiobarbituric acid reacti˝e substances TBARS
TBARS were determined in mouse liver ho-
mogenates immediately after homogenate preparation
w x w xby a fluorescent method 18 with modifications 19 ,
based on the 2-thiobarbituric acid reaction. After the
extraction with n-butanol, the fluorescence was mea-
sured at 515 nm excitation and 555 nm emission. The
values were expressed as nmol TBARSrg tissue.
Malondialdehyde standards were prepared from
1,1,3,3-tetramethoxypropane.
2.6. Hydroperoxide-initiated chemiluminescence of
li˝er homogenates
The homogenates were diluted to a final concentra-
tion of 1 mg of proteinrml in the same buffer, 3 mM
tert-butyl hydroperoxide was added and chemilumi-
nescence was measured at 308C in a Packard Tri-Carb
Model 3320 scintillation counter in the out-of-coinci-
w xdence mode, as previously described 20 . The emis-
sion was expressed in countsrminPmg of protein.
Protein content was assayed by the method of Lowry
w xet al. using bovine serum albumin as standard 21 .
2.7. Glutathione content
Total and oxidized glutathione were determined
after 8, 15 and 22 days of fenofibrate treatment. The
sum of the reduced and oxidized forms of glutathione
X was determined using 5,5 -dithiobis 2-nitrobenzoic
.  .acid DTNB , NADPH and glutathione reductase in
a kinetic assay at 412 nm. Oxidized glutathione
 .GSSG was determined using NADPH and glu-
tathione reductase, at 340 nm. Glutathione concentra-
w xtion was expressed in mmolrg organ 22 . Reduced
 .glutathione GSH content was calculated based on
the measured values of total glutathione and GSSG.
2.8. Lipid-soluble antioxidants
Liver homogenates were extracted with 4 ml of
hexane and then centrifuged for 5 min at 1000=g.
The hexane layer was removed and evaporated to
dryness under nitrogen. The residue was dissolved in
methanolrethanol 1r1 vrv and filtered through a
0.22 mm-pore membrane. For ubiquinols measure-
ments, samples were reduced with NaBH and then4
extracted into 4 ml of hexane following the steps
described above. Measurements of a-tocopherol and
ubiquinols in the methanolrethanol extracts were
made by HPLC on a 8-C reverse phase column with
w xelectrochemical detection 23 . The antioxidant con-
centrations were referred to commercial standards
w xand expressed as nmolrg tissue 24 .
2.9. Statistics
Results are expressed as mean values"S.E.M.
Student’s t test was used to study significance of the
differences between the means of pairs of groups.
w xANOVA and Tukey tests 25 were used to analyze
the differences between mean values of more than
two groups.
2.10. Histopathology
Samples of the liver of mice killed after 1, 2 and 3
weeks of treatment were fixed in a mixture of alco-
hol, acetic acid and formaldehyde and in formol-
w x buffer 26 , and embedded in Histoplast Sistemas
.Analıticos, Buenos Aires . Five mm sections were´
stained with hematoxylin-eosin, PAS and PAS-di-
w xastase following standard procedures 26 . Frozen
sections of the samples fixed in formol-buffer were
w xstained with oil red O 27 .
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3. Results
3.1. H O steady state concentration2 2
The intracellular H O steady state concentration2 2
was measured in the incubation medium of liver
slices of control and fenofibrate-treated animals after
reaching diffusion equilibrium. Administration of
fenofibrate during 2 week induced an increase of
89% in H O steady state concentration control2 2
.  .value: 0.09"0.01 mM Fig. 1
3.2. Spontaneous li˝er chemiluminescence
Spontaneous in situ organ photoemission is highly
sensitive to characterize increased rates of lipoperoxi-
dation. Spontaneous chemiluminescence was deter-
mined in the liver of control and treated mice after 15
days of treatment with fenofibrate. A decrease of
57% was observed in spontaneous chemilumines-
cence, as compared with the control photoemission
 2.  .115"18 cpsrcm Fig. 2 .
( )3.3. Thiobarbituric acid reacti˝e substances TBARS
TBARS were determined in liver homogenates of
control and treated mice after 8, 15 and 22 days of
 .treatment. A slight decrease 15% although non
Fig. 1. Effect of fenofibrate administration on liver H O steady2 2
state concentration. Bars represent mean values"S.E.M., from
six animals. ) P -0.01.
Fig. 2. Spontaneous chemiluminescence and TBARS concentra-
tion in control and fenofibrate-treated mice. Values are the mean
from 4 animals and bars indicate S.E.M. ) P -0.01.
significant, was observed in 15 days fenofibrate-
treated animals as compared with the controls con-
.  .trol value: 0.074"0.004 mmolrg liver Fig. 2 .
3.4. Hydroperoxide-initiated chemiluminescence
The homogenate chemiluminescence initiated by
tert-butyl hydroperoxide was found 56% decreased in
mice treated for 15 days with fenofibrate, as com-
pared with control values 18 400"1140 cpmrmg
.  .protein Table 1 .
3.5. Glutathione content
Total and oxidized glutathione levels were mea-
sured in liver homogenates of control and treated
mice after 8, 15 and 22 days of treatment. Total and
oxidized glutathione increased gradually after fenofi-
Table 1
Hydroperoxide-initiated chemiluminescence and liposoluble an-
tioxidant levels in mice treated with fenofibrate for 15 days and
in control animals
Parameter Control Fenofibrate
)Hydroperoxide-induced 18 377"1138 8 099"519
 .chemiluminescence cpmrmg
) .a-tocopherol nmolrg liver 5.3"0.2 2.6"0.2
) .Ubiquinol-9 nmolrg liver 3.1"0.1 4.8"0.5
) P -0.0005.
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brate administration. Maximal values were obtained
after 22 days of treatment, with increases of 67% and
58% in total and oxidized glutathione content respec-
tively control values for total glutathione: 8.3"0.3
.mmolrg liver; GSSG: 0.20"0.01 mmolrg liver
 .Fig. 3 . An increase of 72% in GSH levels was
observed after 22 days of treatment, as compared
 . with control values 7.9"0.3 mmolrg liver Fig.
. w x w x3 . The ratio GSH r GSSG was not affected by
 .fenofibrate treatment control ratio: 40"3 .
3.6. Lipid soluble antioxidants
Determinations of hepatic levels of a-tocopherol
and ubiquinols were carried out in lipid extracts of
control and 15 days-treated mice. a-tocopherol con-
tent was decreased by 51% after 15 days of treatment
with fenofibrate control value: 5.3"0.2 nmolrg
.liver . An increase of 55% was found in ubiquinols
levels in treated mice, as compared with the controls
 .  .3.1"0.1 nmolrg liver Table 1 .
3.7. Histopathology
The histologic study showed mild microvacuolar
fatty changes in animals killed after 2 and 3 week of
 .treatment Fig. 4 . Enlarged hepatocytes, increased
eosinophilia of the cytoplasm and mild to moderate
 .Fig. 3. Effect of fenofibrate treatment on reduced v and
 .oxidized ‘ glutathione. Symbols indicate mean values from 6
animals and bars indicate S.E.M. ) P -0.01.
 .  .  .Fig. 4. A Liver of control mouse. Oil red O =250 . B
Microvacuolar steatosis in the liver of a mouse treated with
 .fenofibrate. Oil red O =250 .
depletion of glycogen were also observed in fenofi-
 .brate-treated animals figures not included .
4. Discussion
It has been postulated that liver carcinogenesis is
associated to peroxisome proliferation generated by
the oxidative stress resulting from the sustained in-
w xcrease in the peroxisomal generation of H O 2 .2 2
Although the precise mechanism by which intra-
cellular oxidative stress influences initiation and pro-
motion of carcinogenesis remains unknown, it is
generally accepted that H O and other reactive oxy-2 2
gen species can cause DNA damage either directly or
w xby initiating lipid peroxidation 14 .
We had previously reported an increased H O2 2
production together with increases in peroxisomal
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acyl-CoA oxidase activity during peroxisome prolif-
w xeration by fenofibrate treatment 5 . In the present
study, increased H O steady state concentrations2 2
were not correlated with increased rates of lipid
peroxidation. In vivo chemiluminescence was signifi-
cantly decreased by 57% in the liver of fenofibrate-
treated animals and a slight decrease was observed in
TBARS levels. Although both parameters might be
useful to estimate lipid peroxidation, chemilumines-
cence seems to be more sensitive than TBARS. In
vivo chemiluminescence offers a noninvasive and
continuous monitoring of electronically excited
species, mainly singlet oxygen, formed by the free
radical chain oxidation of polyunsaturated fatty acids
w x28 . Our results are consistent with the observations
w xof Huber et al. 29 , that showed a decrease in
TBARS after nafenopin treatment. However, lipid
peroxidation assessed by measuring the levels of
.conjugated dienes in lipid extracts was enhanced in
primary cultures of rat hepatocytes after incubation
w xfor 44 h with nafenopin 6 . Other studies on oxida-
tive injury after various peroxisome proliferator ad-
ministration have shown that TBARS were only
w xslightly increased or even unchanged 30,31 . Goel et
al. suggested that sustained injury to liver cells by
long-term peroxisome proliferation may be necessary
to induce peroxidative damage to membrane lipids
w x14 .
Peroxisome-proliferating agents are also known to
produce numerous alterations in hepatic lipid
metabolism. Lipid accumulation was observed in the
liver of fenofibrate-treated animals. As previously
described by Makowska et al., intrahepatic accumula-
tion of lipid causes an induction of cytochrome
w xP450IVA1 32 . Because of the specificity of
P450IVA1 for fatty acids, this leads to an accumula-
tion of v-hydroxylated fatty acids, which are further
oxidized in the cytosol to dicarboxylic acids prefer-
ential substrates for the peroxisomal b-oxidation sys-
.tem , which then act as the proximal stimulus for
peroxisomal proliferation and hence H O produc-2 2
.tion .
Hydroperoxide-induced chemiluminescence mea-
sures the balance between pro-oxidants and anti-
w xoxidants present in the tissue 33 . Hydroperoxide-in-
duced chemiluminescence was decreased by fenofi-
brate treatment. This can be explained by the pres-
ence of high levels of endogenous antioxidants. In-
creased hydroperoxide-induced chemiluminescence
was associated to antioxidant depletion in several
experimental conditions, such as tumor-bearing ani-
w x w xmals 34 and mitoxantrone treatment 35 . An en-
hancement of the antioxidant response associated to
peroxisome proliferation by fenofibrate, would lead
to an inhibition of the emission.
In our model, glutathione and ubiquinols levels
were increased by fenofibrate treatment. Gray et al.
have suggested that treatments with peroxisome pro-
liferators could lead to increased levels of oxidized
w xglutathione in hepatocytes 36 . This increase could
be due to the degradation by glutathione peroxidase
of high levels of H O , coupled to GSH oxidation2 2
during peroxisome proliferation. Aberg et al. ob-
served that peroxisome proliferators such as clofi-
 .brate and the plasticizer di 2-ethylhexyl phthalate are
w xhighly efficient in increasing liver ubiquinone 15 .
An early report indicated increased liver ubiquinone
content in the mild oxidative stress of depancreatized
w xrats 37 . Ubiquinol has a strong effect in inhibiting
lipid peroxidation in biological systems, such as lipo-
w x w xsomes 23,38 , microsomes 39 and low density lipo-
w xproteins 40 . It has been suggested that ubiquinol
could act as an antioxidant, scavenging lipoperoxyl
radicals and also regenerating tocopheril radicals to
w xa-tocopherol 23,39,41 .
a-Tocopherol levels were lower in the liver of
fenofibrate-treated animals, as compared with control
ones; it appears that a-tocopherol is highly consumed
during peroxisome proliferation. Since a-tocopherol
is normally incorporated into the liver by lipopro-
teins, an impairment of the lipoprotein uptake mecha-
nisms by hypolipidemic drugs would result in a
decrease in vitamin E levels.
Overproduction of hydrogen peroxide, resulting
from increased peroxisomal enzyme activities would
lead to the modulation of the expression of proto-
oncogenes via signal transduction pathways. Carcino-
genicity of these compounds would be related to
active oxygen species produced by proliferated per-
oxisomes, and would not be a consequence of a direct
action of the compound or its metabolites.
In summary, our results indicate that fenofibrate
treatment increases the production of H O , but not2 2
stimulate lipid peroxidation, probably due to the pres-
ence of high levels of some endogenous antioxidants
 .ubiquinols, glutathione . We suggest that carcino-
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genesis would arise from DNA damage produced by
H O and not through lipid peroxidation processes.2 2
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